X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs FULFORD INDIA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA FULFORD INDIA GSK PHARMA/
FULFORD INDIA
 
P/E (TTM) x 59.9 398.8 15.0% View Chart
P/BV x 11.7 6.2 189.0% View Chart
Dividend Yield % 2.1 0.1 2,479.7%  

Financials

 GSK PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
FULFORD INDIA
Mar-14
GSK PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs3,850942 408.7%   
Low Rs2,966450 659.0%   
Sales per share (Unadj.) Rs332.3691.4 48.1%  
Earnings per share (Unadj.) Rs44.311.5 386.5%  
Cash flow per share (Unadj.) Rs47.215.4 307.5%  
Dividends per share (Unadj.) Rs50.002.00 2,500.0%  
Dividend yield (eoy) %1.50.3 510.6%  
Book value per share (Unadj.) Rs202.7380.0 53.4%  
Shares outstanding (eoy) m84.703.90 2,171.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.31.0 1,018.6%   
Avg P/E ratio x76.960.7 126.7%  
P/CF ratio (eoy) x72.245.3 159.2%  
Price / Book Value ratio x16.81.8 917.8%  
Dividend payout %112.917.4 646.8%   
Avg Mkt Cap Rs m288,6432,714 10,633.8%   
No. of employees `0004.60.4 1,038.5%   
Total wages/salary Rs m4,434505 878.0%   
Avg. sales/employee Rs Th6,104.56,073.0 100.5%   
Avg. wages/employee Rs Th961.61,137.4 84.5%   
Avg. net profit/employee Rs Th813.7100.7 808.2%   
INCOME DATA
Net Sales Rs m28,1482,696 1,043.9%  
Other income Rs m1,218125 971.5%   
Total revenues Rs m29,3662,822 1,040.7%   
Gross profit Rs m4,774-46 -10,288.3%  
Depreciation Rs m24815 1,631.6%   
Interest Rs m010 0.0%   
Profit before tax Rs m5,74454 10,578.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,01810 21,020.8%   
Profit after tax Rs m3,75245 8,393.7%  
Gross profit margin %17.0-1.7 -985.6%  
Effective tax rate %35.117.7 198.7%   
Net profit margin %13.31.7 804.1%  
BALANCE SHEET DATA
Current assets Rs m21,4621,738 1,234.6%   
Current liabilities Rs m10,536545 1,934.4%   
Net working cap to sales %38.844.3 87.7%  
Current ratio x2.03.2 63.8%  
Inventory Days Days6848 139.6%  
Debtors Days Days164 381.4%  
Net fixed assets Rs m4,71712 39,639.7%   
Share capital Rs m84739 2,171.8%   
"Free" reserves Rs m16,3081,443 1,130.1%   
Net worth Rs m17,1711,482 1,158.7%   
Long term debt Rs m160-   
Total assets Rs m30,6202,077 1,474.4%  
Interest coverage xNM6.7-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 70.8%   
Return on assets %12.32.6 469.5%  
Return on equity %21.93.0 724.4%  
Return on capital %33.64.3 779.8%  
Exports to sales %00-   
Imports to sales %15.124.5 61.6%   
Exports (fob) Rs m4NA-   
Imports (cif) Rs m4,237659 642.7%   
Fx inflow Rs m51917 3,017.4%   
Fx outflow Rs m8,320673 1,235.9%   
Net fx Rs m-7,801-656 1,189.2%   
CASH FLOW
From Operations Rs m1,38690 1,539.6%  
From Investments Rs m5,010105 4,789.3%  
From Financial Activity Rs m-6,383-14 45,271.6%  
Net Cashflow Rs m12181 6.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 3.8 268.4%  
FIIs % 23.8 0.1 23,800.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 21.2 72.6%  
Shareholders   102,036 4,783 2,133.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS